STAT Summit 2026: As Biotech Shifts, Clear Communication Carries More Weight

STAT Summit returned to Boston on Oct. 14 and 15, bringing together biotech executives, researchers, policymakers and patients. Three themes ran through the two days: AI is changing how drugs are discovered, the industry is working to rebuild trust in science and the U.S. and China are competing for biotech leadership. Each theme depends on how well the industry explains its work.

AI in drug discovery and other advanced scientific tools

Speakers largely framed AI as something that helps scientists rather than hurts them, and several said it will fundamentally change how drugs are made. Conversations centered on precision, including how to identify patient subsets through biomarkers, how to pursue cancers long considered undruggable and how to derisk early-stage programs before costly later trials. Speakers also touched on how more precise medicine can change patient lives.

Precision health was also on display as Dean Y. Li, M.D., Ph.D., executive vice president and president, Merck Research Laboratories and Stephen Hoge, M.D., president, Moderna, spoke about their cancer vaccine, which leverages AI to better personalize each dose for each patient. The companies announced in August that their messenger RNA cancer vaccine significantly delayed cancer recurrence and metastatic disease in melanoma patients. Their next challenge is proving the approach can work in other tumors.

New technologies are also changing how we understand human biology and the diseases that impact us. Harvard researcher Paola Arlotta discussed her work with brain organoids, which she said could change how scientists think about the brain and disease. They can be grown at scale using robotics and from the cells of many people.

Rebuilding trust in science

Speakers asked how technology that is trustworthy becomes technology that is trusted. Communication, access and acceptance came up as the pieces that matter.

The session “Understanding Vaccine Hesitancy” put that question in concrete terms. Cory Anderson of Penn State College of Medicine and Jennifer Reich of the University of Colorado Denver joined STAT’s Nicholas Florko to discuss what motivates the decision to decline a vaccine, especially when culture, religion and personal beliefs influence the healthcare decisions a person makes. One key takeaway for us all: an emotional reaction can follow when science has not been explained well, and scientific communicators need more humility in how they approach these conversations.

How the U.S. and China biotech industries are evolving

Across the two days, the conversations on China were direct. Speakers said the U.S. needs to invest in solutions to compete if it wants to remain part of the global ecosystem.

In “Biotech’s China Problem,” Francisco Gimenez, a partner at 8VC, pointed to clinical trial speed as a place the U.S. lags. He said the efficiency of finding patient cohorts and building programs is one reason the country is behind.

Rep. Jake Auchincloss added a policy angle during his session. Rather than endorse protectionist measures, he argued the U.S. should be better than China. He also gave a preview of a bill he plans to introduce that would allow early-phase trials to bypass pre-approval evaluation. He also warned that politicizing science funding decisions could undermine U.S. biomedical leadership.

What it means for communicators

All three key themes share a common requirement. As the biotech landscape keeps shifting, clear, open and honest communication becomes part of how companies earn their place.

For AI, that means plain language about what the technology does, where scientists remain in charge and what it has yet to prove. For accelerating scientific and industry progress, it means specific claims about speed, investment and clinical progress that can hold up to scrutiny. For trust, it means starting from humility. People who react emotionally to science often have not been given an explanation that respects their questions.

Companies that explain their science openly, acknowledge uncertainty and speak to people on their own terms will be better positioned as policy, funding and competition continue to change. The science shown at STAT Summit was impressive. How the industry talks about it will shape how far that science reaches.

‍